X4 Pharmaceuticals is a single-asset biotech built around Mavorixafor. This is approved for WHIM in the US, and the next step is a label expansion for CN. XFOR’s 4WARD Phase 3 trial in CN will be key.
CHICAGO -- Intracerebroventricular (ICV) delivery of bivalent CAR T-cells targeting EGFR and IL13Rα2 was feasible and appeared safe in patients with recurrent glioblastoma (GBM) in a phase I study ...
It has been reported that granulocyte-colony-stimulating factor(G-CSF) improves cardiac function after myocardial infarction (MI). However, its direct effect on the myocardium and its signaling ...
Department of Hematology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China Objective: The combination of high-dose cyclophosphamide (HD-Cy) (3g/m 2) plus granulocyte ...
Peer ReviewDownload a summary of the editorial decision process including editorial decision letters, reviewer comments and author responses to feedback. Elevated peripheral blood and ...
The United States’ opioid problem has steadily been getting worse. In 2022, more than 110,000 people died of drug overdoses, "two-thirds of whom succumbed to synthetic opioids such as fentanyl," ...
The FDA has approved motixafortide in combination with filgrastim to mobilize hematopoietic stem cells in multiple myeloma transplantation, based on findings from the phase 3 GENESIS trial. The FDA ...
X4 is nearing approval of its lead candidate for WHIM syndrome and aims for label expansion to a much larger market of chronic neutropenias. Despite very small WHIM target population, orphan ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback